A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG

SHR-A2102

DRUG

Adebrelimab injection

DRUG

SHR-8068 injection

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY